Gilead Sciences’ quarterly adjusted earnings came in at $1.87 per share for the quarter ended June, surpassing Zacks Consensus Estimate of $1.76 per share. It was $1.11 per share in the year-ago quarter.
The biopharma company has exceeded consensus EPS estimates four times over the last four quarters.
Gilead’s revenues were $6.22 billion, beating the Zacks Consensus Estimate by 1.14%. Sales were $5.14 billion in the year-ago period. The company beat consensus revenue estimates three times over the last four quarters.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GILD declined for three days, in 130 of 275 cases, the price declined further within the following month. The odds of a continued downward trend are 47%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GILD as a result. In 36 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 43%.
The Moving Average Convergence Divergence Histogram (MACD) for GILD turned negative on September 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 21 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 39%.
Following a +2.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
GILD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 161 of 272 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.949) is normal, around the industry mean (19.199). P/E Ratio (17.844) is within average values for comparable stocks, (34.793). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.025) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 31 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutic products and treatments for life threatening diseases
Industry PharmaceuticalsMajor